All News
Late breaking at #ACR23:
extension of this study for dazodalibep (anti-CD40L) for Sjogren’s symptoms
Another six months with a crossover - & sustained symptomatic benefit after cessation. Fascinating, addresses a desperate clinical need, bring on the phase 3!
ABSTL10 @RheumNow https://t.co/zUfnGEZefj https://t.co/S3lLwhwl85
David Liew drdavidliew ( View Tweet)
Complements & HCQ? (Prof Petri et al)
Significant ⬆️ in C3 (p=0.022) & C4 (p=0.003) levels with HCQ whole blood levels >50 ng/mL
Increasing blood levels of HCQ significantly assocd w/⬆️prob of achieving normal C4
Improving C3,C4; addtl benefit of HCQ?
#ACR23 ABST2327 @RheumNow https://t.co/5ucpXq9ngb
sheila ( View Tweet)
#ACR23 Abstr#2335 A step towards equal access to therapy for ANA+ people with arthritis. A cohort study showed: ANA+ (#SLE, #sjogren, MCTD, UCTD) & arthritis were homogenous related to clinical features, PROs & gene expression score. Offer rationale for basket trial @RheumNow https://t.co/7HTMxE7mSP
Md Yuzaiful Md Yusof ( View Tweet)
HCQ discontinuation in SLE? Why?!
In this retro cohort of 42 pts
Reasons:
Retinal toxicity (57%)
Self-discontinuation (17%)
Factors strongly assoc'd w/ flares 1 yr after discontinuation - mean C3 and +dsDNA at index visit.
#ACR23 ABST2343 @RheumNow https://t.co/BCO9N4gSkX
sheila ( View Tweet)
Im usually super shy on camera but my hair looks great in this video with my friend @RHEUMarampa as we talk about how our reviewer went from a personal project to a fellow study resource. #ACR23 #ACRambassador @RheumNow @cerego https://t.co/KHDni7epFK
Lisa 🐳🗺🧭 rheumarhyme ( View Tweet)
Pain experience in #OA may have different contributing factors
Its a while joint disease!
What are the future targets in #OA being tested? @RheumNow #ACR23 @Tuhina_Neogi https://t.co/lI06pJrdYR
Bella Mehta bella_mehta ( View Tweet)
GCs on MACE in RA in VA
A#2430 #ACR23 @RheumNow
Not just ongoing steroid usage, also prior usage 1 year ago
5 mg use for 30 days one year ago - increases MACE events by 3%
5 mg use for 90 days one year ago - increases MACE events by 9%
Eric Dein ( View Tweet)
Wallace et al. Dose, duration, recency dependent relationship between GC and MACE. Even 5mg/day, 30 day use, and use 1 year prior associated with risk. 5mg, 7.5mg, 10mg pred for 90 days - 13%, 19%, 27% MACE increase Abstr#2430 #ACR23 #ACRbest @RheumNow https://t.co/50B5nGqxu9 https://t.co/lNrUbZOm0o
Richard Conway ( View Tweet)
Even low doses of steroids associated with major adverse cardiovascular events!
Large VA database - >18k RA pts
Dose as low as 5mg/day prednisone for 30 days, 1 year prior to event, associated with increased MACE
@RheumNow #ACR23 Abs#2430 https://t.co/JjeoBi7YTD
Robert B Chao, MD ( View Tweet)
Mok et al. Romosozumab superior to denosumab in high risk GIO. Superior in improving spine BMD. Not fracture. Fracture is what matters. Abstr#2429 #ACR23 @RheumNow https://t.co/5ModHOGsED
Richard Conway ( View Tweet)
A#2429 #ACR23 @RheumNow
ROMO v DEN - 12 mo RCT 70 GIOP pts at high-risk
Mean prednisolone dose 6.6 mg
H/o fragility fx in 1/2 pts
12 mo: Increase in spine BMD- ROMO (+7) and DEN (+2)
Hip and Femoral neck improved both (1.6% both), not signif diff bw grps
AEs: incr injxn site rxn https://t.co/VueuZIjFfM
Eric Dein ( View Tweet)
Physical therapy and lifestyle counseling the main pillars of #OA management are underutilized!
Mainstay remains weight loss and exercise! @RheumNow #ACR23
Rrf memorial lecture @Tuhina_Neogi https://t.co/yXqWIEccq4
Bella Mehta bella_mehta ( View Tweet)
McCormick et al. No improvement in premature mortality gap in gout over time. 19% increased mortality in gout. Independent of serum urate and CV risk factors. Abstr#2428 #ACR23 @RheumNow https://t.co/lSoEvajN3O https://t.co/uWNokm7LCT
Richard Conway ( View Tweet)
Gout mortality
A#2428 #ACR23 @RheumNow
1988-1994 (early) v 2007-2016 (late): Has not improved over time
Independent of serum uric acid
Female gout: increased mortality
Black gout pts also increased
Conclusion: the inflammation, not the uric acid is the risk https://t.co/LTFoSFzaBu
Eric Dein ( View Tweet)
The DICKENS study showed no significant improvement in knee pain(p=0.77), WOMAC pain(p=0.64) or function(p=0.68) & stiffness(p=0.34) between diacerin and pbo over 24wks.
⬆️AEs in diacerin grp-diarrhea, colored urine
#ACR23 ABSTL05 @RheumNow https://t.co/ht0pGN38il
sheila ( View Tweet)
Super interesting SpA phenotypical type world map. #ACR23 Abs #2195 continues to prove how heterogenous this disease is and the need for additional therapeutic agents for improved patient outcomes. https://t.co/hpKY7usUUb @rheumnow https://t.co/xJ1bx6wOC0
Dr. Rachel Tate ( View Tweet)
A#2427 #ACR23 @RheumNow
PR3+ cell abundance higher in prolif LN, more than membranous. Mostly in tuberulointerstitium
Density of PR3+ higher in glomueruli of prolif LN
Correlates with activity, not chronicity
Urinary PR3 predict renal fxn loss at 3y
@jhrheumatology @andreafava https://t.co/vvC8lgZgWO
Eric Dein ( View Tweet)
APTURA 1 study of tocilizumab biosimilar. Not surprisingly no difference. I'm excited about this product. Hopefully be the end to our tocilizumab supply issues and significant societal savings Abstr#0445 #ACR23 @RheumNow https://t.co/qvP7LCeAkm https://t.co/Zb1FUAlXlz
Richard Conway ( View Tweet)
What drives fate of synovial fibroblast into being a lining fibroblast?
Presti et al., organoid culture approach:
-Beta catenin seems instrumental
-Cadherin 23 is specific & drives compaction
Big implications for elective FLS targeted ttmt!
@RheumNow #ACR23 ABST2426 https://t.co/9R5AhwE9rQ
Aurelie Najm ( View Tweet)
Lung cancer in RA. @NamrataRheum et al. 26,625 RA HR for lung cancer for b/tsDMARDs vs csDMARDS 1.07 (0.91-1.26) Abstr#0453 #ACR23 @RheumNow https://t.co/NLNtyYoaoH https://t.co/tRpt62n62X
Richard Conway ( View Tweet)